- Home
- IMTX vs XNCR Comparison
IMTX vs XNCR Comparison
Compare IMTX & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IMTX | XNCR |
|---|---|---|
| Founded | N/A | 1997 |
| Country | Germany | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.1B |
| IPO Year | N/A | 2013 |
Fundamental Metrics
Financial Performance| Metric | IMTX | XNCR |
|---|---|---|
| Price | $10.18 | $17.30 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 11 |
| Target Price | $19.25 | ★ $23.20 |
| AVG Volume (30 Days) | 657.4K | ★ 750.1K |
| Earning Date | 11-17-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $99,445,031.00 | ★ $150,132,000.00 |
| Revenue This Year | N/A | $22.09 |
| Revenue Next Year | $24.39 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 38.16 |
| 52 Week Low | $3.30 | $6.92 |
| 52 Week High | $12.41 | $26.59 |
Technical Indicators
Market Signals| Indicator | IMTX | XNCR |
|---|---|---|
| Relative Strength Index (RSI) | 51.02 | 61.88 |
| Support Level | $9.76 | $15.69 |
| Resistance Level | $12.41 | $17.83 |
| Average True Range (ATR) | 0.87 | 1.00 |
| MACD | 0.01 | 0.07 |
| Stochastic Oscillator | 36.85 | 68.89 |
Price Performance
Historical ComparisonAbout IMTX Immatics N.V.
Immatics NV is a biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.
About XNCR Xencor Inc.
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.